Cullgen utilizes its uSMITE™ platform to selectively degrade disease-causing proteins, including previously undruggable targets. They are focused on developing new chemical entities for diseases lacking effective therapies, such as cancer and autoimmune diseases. In addition to building their own pipeline of protein degradation product candidates, Cullgen is also developing a portfolio of novel E3 ligands. The company was founded in 2018 and is based in San Diego, California.